U.S. Markets closed

Prima Biomed Ltd. (PRR.AX)

Australian Stock Exchange - Australian Stock Exchange Delayed Price. Currency in AUD
Add to watchlist
0.02-0.00 (-4.76%)
As of 11:05AM AEST. Market open.

Prima Biomed Ltd.

95 Pitt Street
Level 12
Sydney, NSW 2000
Australia
61 2 8315 7003
http://www.primabiomed.com.au

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedAge
Mr. Marc VoigtChief Exec. Officer and Exec. Director438.14kN/A44
Ms. Deanne Miller LLBChief Operating Officer, Gen. Counsel and Company Sec.252.75kN/A40
Dr. Frédéric Triebel M.D., Ph.D.Chief Scientific Officer & Chief Medical Officer229.39kN/A62
Mr. Thomas Robert John Bloomfield BA (Hons), A.C.I.S., M.A.I.C.D.Joint Company Sec.N/AN/AN/A
Ms. Larisa ChisholmDirector of Industry Liaison & Devel. and Director of Intellectual PropertyN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Prima BioMed Ltd. engages in the research, development, and commercialization of medical biotechnology products in Australia. The company develops immunotherapeutic products for the treatment of various types of cancer. Its core technologies are based on the LAG-3 immune control mechanism, which plays a vital role in the regulation of the T cell immune response. The company’s lead product candidate is IMP321, a recombinant protein, which is in Phase IIb clinical trials in metastatic breast cancer when used as a chemo-immunotherapy, as well as in Phase I clinical trials in metastatic melanoma. Its other products include IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company is also developing CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. Prima BioMed Ltd. has strategic partnership agreement with Wuxi Biologics Co. Ltd. for developing IMP321 and other LAG-3 related products. Prima BioMed Ltd. is based in Sydney, Australia.

Corporate Governance

Prima Biomed Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.